TY - JOUR T1 - The STELVIO trial, a game changer for bronchoscopic lung volume reduction in patients with severe emphysema JF - Breathe JO - Breathe DO - 10.1183/20734735.0004-2020 VL - 16 IS - 1 SP - 200004 AU - Rein Posthuma AU - Lowie E.G.W. Vanfleteren Y1 - 2020/03/01 UR - http://breathe.ersjournals.com/content/16/1/200004.abstract N2 - Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and airflow limitation, which is caused by small airway disease (bronchiolitis) and alveolar destruction (emphysema) [1]. Patients primarily suffering from severe emphysema are often limited in exercise capacity due to the consequences of hyperinflation [2].The STELVIO trial was crucial to ensure that bronchoscopic lung volume reduction using one-way valves has evolved from an experimental intervention into a state-of-the-art treatment option for specific patients with advanced emphysema http://bit.ly/2IgMrspOur thanks to D.J. Slebos and F. Cleutjens for providing and adapting the figure. ER -